REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2000 participants.

Also called NCT07213778

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 2,000 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07213778
  • EU CT 2025-520479-25-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Greece, Malaysia, Moldova, Spain (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07213778. Randomized; quadruple masking; primary purpose treatment. Start 2025-11-24 (actual); primary completion 2027-05-17 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants
Acronym
ROXI-ASPEN
Condition
Symptomatic Venous Thromboembolism (VTE)
Intervention (Drug)
REGN7508
Intervention (Drug)
Acetylsalicylic Acid (ASA)
Intervention (Drug)
Placebo
Lead sponsor
Regeneron Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct07213778
Content hash
7f1801d54ed89576e244be5e716260300c0c23730a13d5b694e3dd25bd611466